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Abstract
Venous thromboembolism (VTE) is a significant cause of mortality1, yet its genetic determinants 
remain incompletely defined. We performed a discovery genome-wide association study in the 
Million Veteran Program and UK Biobank testing ~13 million DNA sequence variants for 
association with VTE (26,066 cases; 624,053 controls) and meta-analyzed both studies, followed 
by independent replication with up to 17,672 VTE cases and 167,295 controls. We identified 22 
novel loci, bringing the total number of VTE-associated loci to 33 and subsequently fine-mapped 
these associations. We developed a genome-wide polygenic risk score for VTE that identifies 5% 
of the population at equivalent incident VTE risk to carriers of the established F5 Leiden 
(p.R506Q) and prothrombin G20210A mutations. Our data provide new mechanistic insights into 
the genetic epidemiology of VTE and suggest a greater overlap among venous and arterial 
cardiovascular disease than previously suggested.
Editorial summary
Genome-wide analysis of venous thromboembolism identifies 22 new risk loci and facilitates 
construction of a polygenic risk score. Comparison to arterial vascular disease highlights shared 
pathophysiology and potential therapeutic strategies.
Keywords
Venous Thromboembolism; population genetics; genome-wide association studies; cardiovascular 
disease
Venous thromboembolism (VTE) is a complex disease impacted by both environmental1 and 
genetic determinants2,3, and the narrow-sense heritability of VTE has been estimated to be 
approximately 30%4. At the time of analysis, genome-wide association studies (GWAS) 
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revealed only 11 loci reaching genome-wide significance4–10, leaving a significant portion 
of VTE heritability unknown.
Large-scale biobanks linking genetic and diverse phenotypic data in the electronic health 
record (EHR) are being developed throughout the world11,12. Leveraging two large-scale 
biobanks – UK Biobank and the Million Veteran Program (MVP) – we sought to: 1) perform 
a genetic discovery analysis for VTE, 2) evaluate the causal role of blood lipids in VTE, 3) 
further characterize the role of plasminogen activator inhibitor-1 (PAI-1) in VTE, and 4) 
develop and evaluate a genome-wide polygenic risk score (PRS) for VTE.
We designed a two-phased VTE discovery GWAS (Fig. 1, Supplementary Fig. 1). In Phase 
1, we used MVP release 2.1 data and performed testing for association separately among 
individuals of European (whites), African (blacks), and Hispanic ancestry and meta-
analyzed results across ancestral groups. In UK Biobank, association testing was performed 
in individuals of European ancestry. We combined statistical evidence across MVP and UK 
Biobank and set a significance threshold of P < 5 ×10−8 (genome-wide significance), and 
also required an internal replication P < 0.01 in each of the individual MVP and UK 
Biobank analyses, with concordant directions of effect, to minimize false positive findings. 
In Phase 2, an additional round of external replication was performed for lead variants using 
summary data of up to 15,572 VTE cases and 113,430 disease-free controls from the 
INVENT consortium13 combined with 2,100 VTE cases and 53,865 controls from MVP 3.0 
data, requiring P < 0.05 with consistent direction of effect for successful replication.
In MVP, the discovery analysis was composed of 11,844 VTE cases (8,929 white, 2,261 
black, 654 Hispanic) and 211,753 controls from the MVP release 2.1 data. In UK Biobank 
we identified 14,222 VTE cases and 372,102 controls. The baseline characteristics for both 
cohorts are presented in Supplementary Tables 1–2. VTE cases were more likely to be older, 
have a history of smoking, a higher body-mass index, and have type 2 diabetes. Following 
trans-ethnic meta-analysis across MVP and UK Biobank, a total of 2,706 variants at 39 loci 
met a genome-wide significance threshold, with P < 0.01 and concordant effect directions in 
both datasets (Supplementary Fig. 2–5). The F5 Leiden variant, rs6025 (p.R506Q, 
NC_000001.10:g.169519049T>C), was the top association result (2.5% frequency for the T 
allele; OR =2.53; 95%CI: 2.43–2.64; P < 1.0×10−300). We replicated all 11 previously 
described genome-wide VTE loci, and identified 28 candidate novel VTE loci brought 
forward for external replication (Supplementary Tables 3–4). Of the 28 candidate novel loci, 
22 successfully replicated in an independent set of up to 17,672 VTE cases and 167,295 
controls (Supplementary Tables 5–6).
One large randomized controlled trial showed that LDL cholesterol-lowering with a statin 
versus placebo led to a reduced risk of venous thromboembolic events14. We sought to 
explore potential causal relationships of blood lipids with VTE development by performing 
a multivariate Mendelian randomization analysis using a weighted polygenic score of 222 
lipid-associated variants from the Global Lipids Genetics Consortium and summary data 
from the MVP release 2.1 and UK Biobank VTE GWAS restricted to Europeans 
(Supplementary Table 7)15. We observed that a 1-standard deviation of genetically-elevated 
LDL cholesterol was associated with an increased risk of VTE (ORLDL = 1.17, 95% CI 
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=1.05–1.29, PLDL = 0.003). In contrast, both a 1-standard deviation of genetically-elevated 
HDL cholesterol and a 1-standard deviation of genetically-elevated triglycerides were not 
associated with risk of VTE [ORHDL = 1.01, 95% CI =0.91–1.13, PHDL =0.82; 
ORTriglycerides = 0.88, 95% CI =0.77–1.00, PTriglycerides = 0.04] after Bonferroni correction 
(P < 0.016 = [0.05/3 lipid fractions]). An MR-Egger analysis16 indicated no pleiotropic 
biases of our lipid genetic instruments [MR-Egger intercept P > 0.05 for all 3 lipid fractions 
(Supplementary Table 8, Fig. 2)]. A PheWAS (1), an analysis of how DNA sequence 
variants differ in their contribution to vascular disease risk in the arterial and venous 
territories (2), an examination of VTE risk variant-pQTL associations (3), and results of a 
VTE fine-mapping analysis including a 99% credible set of 4 variants at the ZFPM2 locus 
which were genome-wide trans-pQTL associations with plasma PAI-1 concentration (4, 
Supplementary Table 9) are provided in the Supplementary Results.
Given the known role of PAI-1 in venous thrombosis and fibrinolysis in model systems17, 
we hypothesized that the ZFPM2 VTE GWAS and the PAI-1 trans-pQTL associations may 
represent colocalizing signals at the ZFPM2 locus. We used a recently described 
colocalization analysis pipeline18 to compute the colocalization posterior probability (CLPP) 
for the ZFPM2 locus. Using European MVP release 2.1 and UK Biobank European VTE 
meta-analyzed summary statistics, PAI-1 pQTL results in human plasma from the 
INTERVAL study19, and reference LD information of 503 European participants from 1000 
Genomes20 phase 3 whole genome sequencing data, we calculated a CLPP of 0.203 at this 
locus. Previous work suggests that a CLPP > 0.01 is indicative of a “reasonably high” 
probability of colocalization18,21, and the LocusCompare plot at this site further indicates 
that the ZFPM2 VTE GWAS and PAI-1 pQTL associations likely represent a true 
colocalization event (Supplementary Fig. 6).
PAI-1 influences thrombosis by directly inhibiting conversion of plasminogen to plasmin 
and indirectly via disrupting the interaction of circulating monocytes with glycoprotein 
vitronectin within the thrombus and adjacent vein wall22. Monocytes are a key source of 
factor III (tissue factor) as well as matrix metalloproteinases during thrombus clearance23,24. 
Given the colocalization between PAI-1 concentration and human VTE, we sought 
experimentally to determine the impact of PAI-1 levels on venous thrombus size in an 
experimental DVT model utilizing transgenic mice. PAI-1−/− mice have no circulating 
active PAI-1, whereas those overexpressing PAI-1 (PAI-1 Tg), have levels approximately 
137-fold greater than wild-type C57B/L6 (WT) mice25. At 6 days following IVC occlusion 
with generation of thrombus, the PAI-1 overexpressing mice had 1.5-fold larger thrombus 
size compared to PAI-1−/− mice, with the WT mice demonstrating an intermediate 
phenotype. This difference persists during late thrombus resolution, at day 14 (Fig. 3), 
demonstrating progressive impairment in thrombus clearance in the setting of increasing 
PAI-1 protein levels.
Finally, we sought to examine the contribution of polygenic inheritance on VTE risk. 
Currently, the F5 Leiden (p.R506Q) and F2 (prothrombin) G20210A mutations, low-
frequency variants which confer a 2–3-fold risk of VTE, are frequently tested in clinical 
settings to evaluate the role of inherited thrombophilia predisposing to acute thrombotic 
syndromes. Given the individual associations of common genetic variants with VTE, 
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heritable VTE risk may also be explained by an aggregate of common variant VTE risk 
alleles26. We hypothesized that those at the right tail of the normally distributed VTE PRS 
(highest 5%) would be at significantly increased VTE risk (Fig. 4a).
We generated a 297-variant VTE PRS using a pruning and thresholding method (R2 < 0.2, P 
< 1×10−5) from European MVP release 2.1 and UK Biobank European VTE meta-analyzed 
summary statistics (Supplementary Table 10). Notably, we excluded the LD blocks (R2 > 
0.2) containing the F5 p.R506Q and F2 G20210A variants from the PRS. We first assessed 
the associated VTE risk for the 5% of individuals with the highest PRSVTE relative to the 
rest of the population using prevalent data from MVP release 3.0, a set of 2,100 VTE cases 
and 53,865 VTE controls entirely independent from the individuals in the MVP discovery 
GWAS. We observed that the 2,798 individuals in MVP release 3.0 with the 5% highest 
PRSVTE had 2.89-fold increased risk of VTE relative to the rest of the population (ORPRS = 
2.89, 95% CI =2.52–3.30, PPRS =7.2×10−53). This effect estimate was similar in magnitude 
to those observed for F5 p.R506Q (ORF5 = 2.97, 95% CI = 2.63–3.36, PF5 =3.4×10−67) and 
F2 G20210A (ORF2 = 2.61, 95% CI = 2.19–3.12, PF2 =5.2×10−27) [Fig. 4b]. In addition, we 
observed that this risk was further compounded for individuals among the top 5% with 
increased polygenic VTE risk who were also F5 Leiden or F2 G20210A carriers.
We sought replication of our PRS findings using incident VTE data from the prospective 
Women’s Health Initiative (WHI) Hormone Trial (HT). In total, among 10,975 European 
women prospectively followed for up to 25 years in the WHI-HT, 690 incident VTE events 
were identified among participants with genetic data. Demographic and clinical 
characteristics for WHI participants in our VTE incident event analysis are shown in 
Supplementary Table 11. We estimated the risk for carriers of F5 p.R506Q and F2 G20210A 
mutations as well as those among the 5% highest PRSVTE through Cox proportional hazards 
models. We observed that F5 p.R506Q carriers were at greater than 2-fold risk of developing 
VTE [Hazard Ratio (HRF5) = 2.34, 95% CI = 1.86–3.35, PF5 =2.8×10−13], and the F2 
G20210A mutation was nominally associated with increased VTE risk [HRF2 = 3.35, 95% 
CI = 1.10–10.23, PF2 =0.033]. The 549 individuals in WHI with the 5% highest PRSVTE had 
2.51-fold risk of incident VTE relative to the rest of the population [HRPRS = 2.51, 95% CI 
=1.97–3.19, PPRS =4.4×10−14] as depicted in Figure 5. Much like in MVP, the risk among 
the 5% of the population with the highest PRSVTE in WHI was comparable in effect size to 
that of large-effect, monogenic mutations in F5 and F2.
These findings permit several conclusions. First, our results lend human genetic support to 
LDL cholesterol lowering as a preventive strategy for VTE. In the JUPITER (Justification 
for the Use of statins in Prevention: an Interventional Trial Evaluating Rosuvastatin) trial, 
administration of 20mg of rosuvastatin in asymptomatic participants resulted in a reduced 
occurrence of symptomatic VTE14. This implies that the apparent VTE risk reduction from 
statins may be due to on-target lowering of lipoproteins, much like the benefits observed for 
multiple atherosclerotic syndromes27,28. Second, partial antagonism of PAI-1 as a preventive 
treatment for VTE deserves further consideration. In our analysis, we noted colocalizing 
ZFPM2 VTE GWAS and PAI-1 pQTL associations and observed PAI-1 overexpressing mice 
had 1.5-fold larger thrombus size compared to PAI-1−/− mice in an inferior vena cava 
ligation model. These results suggest that imbalance in the thrombosis-fibrinolysis 
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pendulum in the human condition may lead to development of pathologic VTE, whereas 
lower active PAI-1 levels may allow for resolution of incidental venous thrombosis prior to 
becoming clinically relevant. Third, our data provide further evidence for the utility of 
polygenic risk prediction in the clinical realm. In a recent publication by Khera and 
colleagues29, the authors generated expanded PRS, and demonstrate that those within the 
right tail of the distribution have a >3-fold increased risk of developing the disease, akin to 
carriers of monogenic mutations. We build on these findings by extending polygenic scoring 
to incident VTE events, where we observed similar magnitudes of effect for our PRSVTE and 
the F5 p.R506Q/F2 G20210A mutations. Our data suggest that extending current 
thrombophilia genetic panels to include testing for polygenic VTE risk would significantly 
increase the yield of current genetic testing and may be warranted.
Our study should be interpreted within the context of its limitations. First, our VTE 
phenotype is based on EHR data and may result in misclassification of case status. Such 
misclassification should, however, reduce statistical power for discovery and bias results 
toward the null. Second, while our colocalization analysis and murine functional data 
support the role of PAI-1 in VTE, further research is needed to fully understand the causal 
variant at the ZFPM2 locus and its underlying mechanism. Lastly, while those with the 
highest PRSVTE are at increased risk for VTE, the PRS’s mechanism of action represents a 
combination of many causal risk factors, rather than one single pathway that leads to 
disease. However, assessment of individual risk may help identify a subpopulation more 
likely to benefit from thromboprophylaxis during periods of increased risk - for instance 
perioperatively30 or during hospitalizations for acute, medical illness31.
In conclusion, our data provide new mechanistic insights into the genetic epidemiology of 
VTE and suggest a greater intersection between blood lipids, VTE, and arterial vascular 
disease than previously understood.
Online Methods
Study Populations
We conducted genetic association analyses using DNA samples and phenotypic data from 
two cohorts: the Million Veteran Program (MVP) and UK Biobank. In MVP, individuals 
aged 19 to over 100 years were recruited from 63 VA Medical Centers across the United 
States. In our initial MVP analysis, we evaluated 11,844 VTE cases (8,929 white, 2,261 
black, 654 Hispanic) and 211,753 VTE-free controls.
In UK Biobank, individuals aged 45 to 69 years old were recruited from across the United 
Kingdom for participation. In this study, we identified 14,222 VTE cases and 372,102 
controls of European ancestry. Further details of cohort descriptions and disease definitions 
are described in the Supplementary Note. All studies received ethical and study protocol 
approval by their appropriate Institutional Review Boards and informed consent was 
obtained from all participants. Additional information regarding experimental design and 
participants are provided in the Life Sciences Reporting Summary.
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In addition, we examined incident VTE data from the WHI randomized clinical trial of 
Hormone Therapy (HT) for our PRS analysis. The overall design of the WHI study has been 
described previously32. In brief, at the inception of the WHI study (1993–1998), 161,808 
postmenopausal women between the ages of 50 and 79 years were eligible for inclusion in 
multiple clinical trials. Exclusion criteria related to the presence of medical conditions 
predisposing to shortened survival or safety concerns. The protocol and consent forms were 
approved by institutional review committees and all participants provided written informed 
consent. The WHI-HT initially comprised 27,347 postmenopausal women who were 
randomized to receive either estrogen plus progestin or estrogen alone versus placebo until 
the trials were stopped early in July 2002 and March 2004, respectively. All WHI-HT 
participants subsequently continued to be followed without intervention until close-out. Of 
the various components of WHI, VTE was adjudicated by physician adjudicators for 
participants who were enrolled in the HT trials.
Genetic Data and Quality Control for Association Analysis
DNA extracted from whole blood was genotyped in MVP using a customized Affymetrix 
Axiom biobank array, the MVP 1.0 Genotyping Array. Veterans (U.S. military personnel) of 
three mutually exclusive ethnic groups were identified for analysis: 1) non-Hispanic whites 
(European ancestry), 2) non-Hispanic blacks (African ancestry), and 3) self-identified 
Hispanics. After pre-phasing using EAGLE33 v2, genotypes from the 1000 Genomes 
Project20 phase 3, version 5 reference panel were imputed into MVP participants via 
Minimac3 software34. Ethnicity-specific principal component analysis was performed using 
the EIGENSOFT software35. Additional details of quality control procedures used to assign 
ancestry and perform genotype imputation are described in the Supplementary Note.
In MVP, sample and variant quality control was performed as previously described36. In 
brief, duplicate samples, samples with more heterozygosity than expected, an excess 
(>2.5%) of missing genotype calls, or discordance between genetically inferred sex and 
phenotypic gender were excluded. In addition, one individual from each pair of related 
individuals (kinship > 0.0884 as measured by the KING37 software) were removed. In total, 
we identified 312,571 multi-ethnic participants passing quality control from the MVP 
release 2.1 data (used in association analysis), and another 69,578 from the MVP release 3.0 
data used for the PRS analysis.
Following imputation, variant-level quality control was performed using the EasyQC R 
package38 and exclusion metrics included: ancestry-specific Hardy-Weinberg equilibrium P 
<1×10−20, posterior call probability < 0.9, imputation quality <0.3, minor allele frequency 
(MAF) < 0.0003, call rate < 97.5% for common variants (MAF > 1%), and call rate < 99% 
for rare variants (MAF < 1%). Variants were also excluded if they deviated > 10% from their 
expected allele frequency based on reference data from the 1000 Genomes Project20. 
Following variant-level quality control, we obtained 19.9 million, 31.9 million, and 28.1 
million DNA sequence variants for analysis in white, black, and Hispanic participants, 
respectively.
In UK Biobank, analysis was performed separately in white individuals after genotyping 
using either the UK BiLEVE or UK Biobank Axiom Arrays. Approximately 500,000 
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individuals were genotyped and subsequently imputed to the haplotype reference consortium 
(HRC) and UK10K reference panels (UK Biobank v3 release). Details of these procedures 
are described elsewhere39. We performed genome-wide association testing for VTE in the 
UK Biobank using all variants in the v3 release with MAF > 0.3% and imputation quality 
INFO > 0.4. To avoid potential population stratification, only European-ancestry samples 
were included in the analysis. This subset was selected based on self-reported white 
ethnicity that was subsequently confirmed using genetic principal components analysis. 
Outliers within the self-reported white samples in the first 6 principal components of 
ancestry were detected and subsequently removed using the R package aberrant40. In 
addition, individuals with sex chromosome aneuploidy (neither XX or XY), discordant self-
reported and genetic sex, or excessive heterozygosity or missingness, as defined centrally by 
the UK Biobank were removed. Finally, one individual from each pair of second-degree or 
closer relatives (kinship > 0.0884) was removed, selectively retaining VTE cases when 
possible.
VTE Discovery Association Analysis
In MVP, genotyped and imputed DNA sequence variants were tested for association with 
VTE through logistic regression adjusting for age, sex, and 5 principal components of 
ancestry assuming an additive model using the SNPTEST (mathgen.stats.ox.ac.uk/
genetics_software/snptest/snptest.html) statistical software program. In our discovery 
analysis, we performed association analyses using MVP release 2.1 data separately for each 
ancestral group (whites, blacks, and Hispanics) and then meta-analyzed using an inverse-
variance weighted fixed effects method implemented in the METAL software program41. We 
excluded variants with a high amount of heterogeneity (I2 statistic > 75%) across the three 
ancestries. In UK Biobank, association testing was performed using a logistic regression 
model adjusted for age at baseline, sex, genotyping array, and the first 5 principal 
components of ancestry. All testing was performed in PLINK2 (https://www.cog-
genomics.org/plink/2.0/).
We combined results across MVP release 2.1 and UK Biobank cohorts using inverse-
variance weighted fixed effects meta-analysis and set a significance threshold of P < 5 ×10−8 
(genome-wide significance). In addition, we also required an internal replication P < 0.01 in 
each of the MVP and UK Biobank analyses (e.g. MVP discovery and subsequent UK 
Biobank replication, and vice versa), with concordant direction of effect, to minimize false 
positive findings. Novel loci were defined as being greater than 500,000 base-pairs away 
from a known VTE genome-wide associated lead variant. Additionally, European linkage 
disequilibrium information from the 1000 Genomes Project20 was used to determine 
independent variants where a locus extended beyond 500,000 base-pairs. All logistic 
regression P values were two-sided. For X chromosome analyses, male genotypes were 
coded as if they were homozygous diploid for the observed allele.
Replication
In Phase 2, an additional round of external replication was performed for lead variants using 
summary data of up to 15,572 VTE cases and 113,430 disease-free controls from the 
INVENT consortium’s current VTE meta-analysis13 combined with 2,100 VTE cases and 
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53,865 controls from MVP 3.0 data. Of note, UK Biobank data was excluded from the 
summary statistics provided by INVENT. We defined significant novel associations as those 
that were at least nominally significant in replication (P<0.05) with consistent direction of 
effect and had an overall P < 5×10−8 (genome-wide significance) in the discovery and 
replication cohorts combined.
Venous Thromboembolism Disease Definitions
From the 312,571 multi-ethnic participants in MVP release 2.1, and 69,578 European 
participants in MVP release 3.0, individuals were defined as having VTE based on 
possessing at least two of the ICD-9/10 codes outlined in Supplementary Table 12 in their 
EHR. Individuals were defined as controls if did not meet the definition of a VTE case and 
their EHR reflected 2 or more separate encounters in the Veterans Affairs Healthcare System 
in each of the two years prior to enrollment in MVP. In UK Biobank, individuals were 
defined as having VTE based on the definition by Klarin and colleagues as previously 
described4. All other individuals were defined as controls.
Lipids and VTE Mendelian Randomization Analysis
Summary-level data for 222 genome-wide lipids-associated variants were obtained from the 
publicly available data from the Global Lipids Genetics Consortium15 using a previously 
described genetic risk score instrument36. As previously described, cohorts either excluded 
participants on statins or adjusted total cholesterol and LDL cholesterol (by dividing by 0.8 
or 0.7, respectively) if a statin was prescribed. One variant, rs77375493, was excluded from 
the current analysis after not passing quality control. We then utilized results from the MVP 
and UK Biobank GWAS meta-analysis restricted to Europeans. The effect alleles were 
matched with all lipid and VTE summary data and 3 different Mendelian randomization 
analyses were performed: 1) inverse-variance weighted; 2) multivariable; 3) MR-Egger to 
account for pleiotropic bias. First, we performed inverse-variance weighted Mendelian 
randomization using each set of variants for each lipid trait as instrumental variables. This 
method, however, does not account for possible pleiotropic bias. Therefore, we next 
performed inverse-variance weighted multivariable Mendelian randomization. This method 
adjusts for possible pleiotropic effects across the included lipid traits in our analyses using 
effect estimates from the variant-VTE outcome and effect estimates from variant-LDL 
cholesterol, variant-HDL cholesterol, and variant-triglycerides as predictors in 1 
multivariable model. We additionally performed MR-Egger as previously described16. This 
technique can be used to detect bias secondary to unbalanced pleiotropy in Mendelian 
randomization studies. In contrast to inverse-variance weighted analysis, the regression line 
is unconstrained, and the intercept represents the average pleiotropic effects across all 
variants. Bonferroni-corrected 2-sided P values (P=0.016; 0.05/3) for 3 tests were used to 
declare statistical significance. Analysis was performed using the R software program 
(version 3.2.1; Vienna, Austria).
Colocalization of ZFPM2 VTE GWAS and PAI-1 plasma pQTL Signals
To evaluate whether there was evidence of colocalization across the VTE GWAS and PAI-1 
pQTL studies, we used European MVP release 2.1 and UK Biobank European VTE meta-
analyzed summary statistics and PAI-1 pQTL results from the INTERVAL study19. For the 
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2,178 variants within the 1-megabase region surrounding the lead ZFPM2 lead VTE GWAS 
variant, we performed a locus-wide colocalization analysis using FINEMAP42 to generate 
posterior causal probabilities for each of these variants in the GWAS and the pQTL analyses. 
We used the European superpopulation subset of the 1000 Genomes20 phase 3 whole 
genome sequence data as a reference for the linkage disequilibrium statistics, and assumed 
only 1 causal variant at the locus. We then analyzed these posterior probabilities with a 
publicly available pipeline18 to compute the CLPP for the entire locus as previously 
described21. The R package LocusCompareR was used to visualize the colocalizing signals.
Functional Assessment of PAI-1 in Murine Models
Male C57BL/6 (WT) mice (Jackson Laboratory, Farmington, CT), PAI-1−/− (backcrossed 
5–10 generations on C57BL/6 mice) and PAI-1 over-expressing mice (PAI-1 Tg, 
backcrossed 5–10 generations on C57BL/6 background) were utilized in this study25,43,44. 
Previous data comparing homozygous littermates to wild type C57BL/6 controls 
demonstrated identical phenotype with regards to venous thrombosis with regards to size 
and cellular composition25,44. Therefore, in the interest of humane and responsible animal 
use, wild type C57BL/6 mice (WT) were utilized as controls. Animals underwent a well-
characterized DVT model, stasis inferior vena cava (IVC) thrombosis, at 8–10 weeks of age 
and 20–25 grams body weight24,25,45–47. Isoflurane 2% was administered as inhaled 
anesthetic. A midline laparotomy was performed, the retroperitoneum exposed, and dorsal 
IVC branches were interrupted with electrocautery. The infrarenal IVC and any 
accompanying side branches caudal to the left renal vein were ligated with 7–0 prolene 
(Ethicon, Inc., Somerville, NJ) to generate blood stasis. A running continuous 5–0 Vicryl 
suture was used to close the fascia and Vetbond tissue adhesive was applied for skin closure 
(3M Animal Care Products, St. Paul, MN). Mice were euthanized at 6 and 14 days post-
thrombosis. The IVC and its associated thrombus were weighed (grams) and measured 
(centimeters) for weight to length analysis of thrombus size24,48,49. GraphPad Prism 
software version 6.0 was used to analyze the thrombus size. Data is presented as the mean +/
− the standard deviation. Statistical significance amongst multiple groups was determined 
using one-way analysis of variance followed by Tukey’s multiple comparisons post hoc test. 
A value of P < 0.05 was considered significant. All work was approved by the University of 
Michigan, University Committee on Use and Care of Animals and was performed in 
compliance with the Guide for the Care and Use of Laboratory Animals published by the US 
National Institutes of Health.
VTE Polygenic Risk Score Generation
Polygenic risk scores (PRS) represent an individual’s risk of a given disease conferred by 
the cumulative impact of many common DNA sequence variants. A weight is assigned to 
each genetic variant based on its strength of association with disease risk (β). Individuals are 
then additively scored in a weighted fashion based on the number of risk alleles they carry 
for each variant in the PRS.
To generate our score, we used summary statistics from the combined MVP release 2.1 and 
UK Biobank VTE summary statistics restricted to Europeans (23,151 VTE cases, 553,439 
controls) and a linkage disequilibrium panel of 20,000 randomly selected European samples 
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from UK Biobank. We restricted variants to those present in both MVP release 2.1 and UK 
Biobank VTE summary statistics with a consistent direction of effect. To increase the 
number of independent variants included in our score, we performed a pruning and 
thresholding analysis using the linkage disequilibrium-driven clumping procedure in PLINK 
version 1.90b (--clump). In brief, this algorithm formed “clumps” around variants with VTE 
association P < 1×10−5 and with an R2 > 0.2 based on the linkage disequilibrium reference. 
From our initial set of summary statistics, the algorithm selects only 1 associated variant 
from each clump below our pre-specified P value threshold. The final output from this 
procedure generated a score of 299 independent (R2 <0.2), VTE associated (P < 1×10−5) 
variants, representing the strongest disease-associated variant for each linkage 
disequilibrium-based clump across the genome. From this 299 variant PRS, we then 
removed the clumps containing the F5 p.R506Q and F2 G20210A variants, resulting in a 
297 variant PRSVTE for downstream analysis.
VTE Polygenic Risk Score Analysis
From the 69,578 MVP release 3.0 participants (none of whom were included in the VTE 
discovery analysis), we identified 2,100 prevalent VTE cases and 53,865 controls. We first 
assessed the associated VTE risk for the 5% of individuals with the highest PRSVTE relative 
to the rest of the population using logistic regression adjusting for age, sex, and 5 principal 
components of ancestry. We then tested the association of the F5 p.R506Q and F2 G20210A 
variants among the 5% of individuals with the highest PRSVTE relative to the rest of the 
population in the MVP release 3.0 data using an identical logistic regression model.
We replicated our findings using incident VTE data from the WHI. Data used in this analysis 
included genetic data from WHI-HT participants derived from three separate GWAS sub-
studies: 1) the WHI Genomics and Randomized Trials Network study (WHI-GARNET, 457 
incident VTE events among 4,233 participants), (2) the WHI Memory Study (WHIMS, 180 
incident VTE events among 5,637 participants), and (3) the WHI Long Life Study (WHI-
LLS, 53 incident VTE events among 1,105 participants). All individuals included in the 
incident event analysis were of European ancestry. Specific details of each WHI sub-study 
including genotyping, study design, and imputation are included in the Supplementary Note. 
Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% 
confidence intervals for the associations of the F5 p.R506Q and F2 G20210A mutations with 
VTE adjusting for age, 10 principal components of ancestry, and hormone therapy 
intervention status during the active phase of the WHI-HT. We then tested the associated 
VTE risk for the 5% of individuals with the highest PRSVTE relative to the rest of the 
population using Cox proportional hazards models adjusting for age, 10 principal 
components of ancestry, and hormone therapy intervention status during the active phase of 
the WHI-HT. Results from WHIMS, WHI-LLS, and WHI-GARNET were combined using 
an inverse-variance weighted fixed effects meta-analysis. Bonferroni-corrected 2-sided P 
values (P=0.016; 0.05/[2 variants + 1 PRSVTE) for 3 tests were used to declare statistical 
significance. Analyses were performed using the R software program (version 3.2.1).
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Data availability
The full summary level association data from the MVP trans-ancestry VTE meta-analysis 
from this report are available upon request through dbGAP, accession code 
phs001672.v2.p1. Data contributed by CARDIoGRAMplusC4D investigators are available 
online (http://www.CARDIOGRAMPLUSC4D.org/). Data on large artery stroke have been 
contributed by the MEGASTROKE investigators and are available online (http://
www.megastroke.org/). The genetic and phenotypic UK Biobank data are available upon 
application to the UK Biobank.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Venous thromboembolic disease genetic discovery and replication study design.
In UK Biobank, we performed an association analysis for DNA sequence variants in 14,222 
VTE cases and 372,102 controls of European ancestry using logistic regression. These 
results were combined with association statistics from DNA sequence variants across 3 
mutually exclusive ancestry groups in the Million Veteran Program release 2.1 data 
representing 11,844 VTE cases and 251,951 controls. Data from UK Biobank and MVP 
were meta-analyzed using an inverse-variance weighted fixed effects method. We set a 
significance threshold of two-sided P < 5 ×10−8 (genome-wide significance), and also 
required an internal replication two-sided P < 0.01 in each of the MVP and UK Biobank 
analyses, with concordant direction of effect, to minimize false positive findings. We 
subsequently performed external replication using summary data from the INVENT 
consortium (up to 15,572 VTE cases and 113,430 controls) meta-analyzed with data from 
MVP 3.0 (2,100 VTE cases and 53,865 controls), requiring an external replication P < 0.05 
with a consistent direction of effect.
Abbreviations: MVP, Million Veteran Program; VTE, Venous thromboembolism; PCs, 
Principal Components
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Figure 2. Blood lipids and VTE risk.
Association of the 222 variant lipid genetic risk score with VTE in a multivariable 
Mendelian randomization analysis. Logistic regression odds ratios are displayed per 1-
standard deviation genetically increased a) LDL cholesterol, b) HDL cholesterol, and c) 
triglycerides. Wald statistic two-sided values of P are displayed. Summary-level lipids data 
from up to 319,677 participants of the Global Lipids Genetics Consortium15, and VTE 
association data from MVP (N = 8,929 cases; 181,337 controls) and UK Biobank (N = 
14,222 cases; 372,102 controls) were used for this analysis. Gray boxes reflect the inverse-
variance weight for each study.
Abbreviations: HDL, High-Density Lipoprotein; LDL, Low-Density Lipoprotein; MVP, 
Million Veteran Program; UKB, UK Biobank
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Figure 3. Functional assessment of PAI-1 in murine models.
Inferior vena cava venous thrombus size was measured at day 6 and day 14 after inferior 
vena cava ligation in PAI-1 Tg (day 6 N = 19; day 14 N = 20), wild type (day 6 N = 20; day 
14 N = 49), and PAI-1 −/− mice (day 6 N =23; day 14 N =27). Thrombus size was observed 
to be larger in the PAI-1 Tg mice compared to PAI-1−/− mice (one-way analysis of variance 
followed by Tukey’s multiple comparisons post hoc test, *p=0.02, ****p<0.0001). A scatter 
dot plot depicting mean thrombus size ± standard deviation is shown.
Abbreviations: PAI-1, Plasminogen Activator Inhibitor-1; Tg, Transgenic; WT, Wild Type
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Figure 4. Genome-wide polygenic risk score for VTE.
a) Distribution of the PRSVTE in the MVP release 3.0 dataset (n = 55,965). The x-axis 
represents the PRS with values transformed to have a mean of 0 and standard deviation of 1. 
The region shaded in blue represents those with the highest 5% of PRSVTE values.
b) VTE odds ratios in MVP release 3.0 data for carriers of the F5 p.R506Q and F2 G20210A 
mutations. In addition, the odds ratio for individuals with the highest 5% PRSVTE compared 
to individuals among the lower 95% of PRSVTE, as well as for carriers of the F5 p.R506Q 
and F2 G20210A mutations within the highest 5% PRSVTE are depicted. Wald statistic two-
sided values of P are displayed.
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Abbreviations: VTE, Venous Thromboembolism; PRS, Polygenic Risk Score; Chr, 
Chromosome; MVP, Million Veteran Program; CI, Confidence Interval
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Figure 5. Genome-wide polygenic risk score and incident VTE events.
Hazard ratios calculated from the Cox Proportional hazards model for incident VTE events 
in the Women’s Health Initiative study for carriers of the F5 p.R506Q and F2 G20210A 
mutations. The hazard ratio for individuals with the highest 5% PRSVTE compared to 
individuals among the lower 95% of PRSVTE is also depicted. Two-sided values of P are 
displayed.
Abbreviations: VTE, Venous Thromboembolism; PRS, Polygenic Risk Score; Chr, 
Chromosome; CI, Confidence Interval
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